IL111007A - תכשירים המכילים ראפאמיצין למתן דרך הפה - Google Patents

תכשירים המכילים ראפאמיצין למתן דרך הפה

Info

Publication number
IL111007A
IL111007A IL111007A IL11100794A IL111007A IL 111007 A IL111007 A IL 111007A IL 111007 A IL111007 A IL 111007A IL 11100794 A IL11100794 A IL 11100794A IL 111007 A IL111007 A IL 111007A
Authority
IL
Israel
Prior art keywords
rapamycin
composition
solution
phospholipid
per
Prior art date
Application number
IL111007A
Other languages
English (en)
Other versions
IL111007A0 (en
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL111007A0 publication Critical patent/IL111007A0/xx
Publication of IL111007A publication Critical patent/IL111007A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL111007A 1993-09-30 1994-09-19 תכשירים המכילים ראפאמיצין למתן דרך הפה IL111007A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12952993A 1993-09-30 1993-09-30
US08/301,179 US5536729A (en) 1993-09-30 1994-09-09 Rapamycin formulations for oral administration

Publications (2)

Publication Number Publication Date
IL111007A0 IL111007A0 (en) 1994-11-28
IL111007A true IL111007A (he) 1998-06-15

Family

ID=26827654

Family Applications (1)

Application Number Title Priority Date Filing Date
IL111007A IL111007A (he) 1993-09-30 1994-09-19 תכשירים המכילים ראפאמיצין למתן דרך הפה

Country Status (8)

Country Link
US (1) US5536729A (he)
JP (1) JP3807753B2 (he)
KR (1) KR100452004B1 (he)
CN (1) CN1108152C (he)
BR (1) BR9403948A (he)
CA (1) CA2133177C (he)
IL (1) IL111007A (he)
TW (1) TW420607B (he)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TR199903065T2 (xx) * 1997-06-13 2000-09-21 American Home Products Corporation Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
JP4620405B2 (ja) * 2004-08-02 2011-01-26 アサヒビール株式会社 酵母変異株、グルタチオン高含有酵母の製造方法、その培養物、その分画物、酵母エキスおよびグルタチオン含有飲食品
WO2006050461A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
JP2008533204A (ja) * 2005-03-21 2008-08-21 マクサイト， インコーポレイテッド 病気又は症状の治療のためのドラッグ送達システム
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3
EP1871343A2 (en) * 2005-04-12 2008-01-02 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
US8252326B2 (en) * 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
US8492400B2 (en) * 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CA2634473A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
CN1919194A (zh) * 2006-08-17 2007-02-28 刘瑜玲 西罗莫司的液体组合物
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2010090654A1 (en) * 2009-02-05 2010-08-12 Tdt, Ltd. Methods of reducing the proliferation and viability of microbial agents
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
CN101554376B (zh) * 2009-05-06 2011-11-30 北京大学 一种高生物利用度的雷帕霉素组合物及制备方法
US8716307B2 (en) 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2515883A4 (en) * 2009-12-22 2013-07-17 Abbvie Inc CAPSULE OF ABT-263
GB201006012D0 (en) * 2010-04-09 2010-05-26 Ayanda As Composition
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
KR101253399B1 (ko) * 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
ES2952038T3 (es) * 2016-04-05 2023-10-26 Univ New York State Res Found Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune
US10668011B2 (en) 2016-06-30 2020-06-02 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
WO2019104065A1 (en) * 2017-11-22 2019-05-31 Turrinii Pharmaceutical, Llc Anti-aging methods and compositions
AU2019363244B2 (en) 2018-10-15 2024-10-03 Cipla Limited Pharmaceutical formulation
WO2021146200A1 (en) 2020-01-13 2021-07-22 Building Materials Investment Corporation Impact resistant roofing systems and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB8920013D0 (en) * 1989-09-05 1989-10-18 Kelly H P G Improvements in or relating to the control of linear motors
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin

Also Published As

Publication number Publication date
CA2133177A1 (en) 1995-03-31
CN1108931A (zh) 1995-09-27
CA2133177C (en) 2004-08-17
KR100452004B1 (ko) 2005-09-05
US5536729A (en) 1996-07-16
IL111007A0 (en) 1994-11-28
JP3807753B2 (ja) 2006-08-09
TW420607B (en) 2001-02-01
CN1108152C (zh) 2003-05-14
KR950007859A (ko) 1995-04-15
JPH07196519A (ja) 1995-08-01
BR9403948A (pt) 1995-06-13

Similar Documents

Publication Publication Date Title
US5536729A (en) Rapamycin formulations for oral administration
CA2133175C (en) Rapamycin formulations for oral administration
US5989591A (en) Rapamycin formulations for oral administration
US5985325A (en) Rapamycin formulations for oral administration
EP0648494B1 (en) Rapamycin formulations for oral administration
JP2009298823A (ja) 経口投与用ラパマイシン処方
EP0650730A1 (en) Rapamycin formulations for oral administration
AU743584B2 (en) Rapamycin formulations for oral administration
HK1010342B (en) Rapamycin formulations for oral administration
HK1015677B (en) Rapamycin formulations for oral administration
MXPA98002008A (en) Formulations of rapamycin for administration or

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired